Cipher Pharmaceuticals combines 50%+ EBITDA margins, debt-free optionality, and reimbursement-driven catalysts into an underappreciated specialty-pharma compounder.
Overview
Cipher Pharmaceuticals is a streamlined specialty-pharma company built around acquired and in-licensed late-stage products rather than capital-intensive discovery. Its Canadian dermatology franchise is anchored by Epuris, which holds 47% of the oral isotretinoin market, while Natroba provides a high-margin US commercial platform with 83%–87% gross margins and 23% market share. **The near-term investment case depends on Epuris reimbursement expansion and recovery of Natroba volumes after Medicaid exclusions.** The July 6, 2026 pCPA LOI could broaden Epuris public coverage, Health Canada accepted the Natroba submission on January 28, 2026, and MOB-015 offers a potentially disruptive Canadian onychomycosis opportunity. Q2 2026 revenue fell 10% year over year to US$12.1 million, but Canadian product revenue rose 12% to US$4.6 million and adjusted EBITDA remained US$6.8 million, or a 56.2% margin. Cipher was debt-free with US$9.1 million of cash and US$90 million of available credit capacity at June 30, 2026. **At CAD 17.55, the stock trades below the CAD 20.97 DCF value, CAD 18.50–23.50 intrinsic range, and CAD 20.64 analyst consensus target.**